Skip to content

CELU

Celularity Inc

NASDAQ · Healthcare · Biotechnology · US

$1.16
−7.20%
Ask drillr

Year over year

Reported trailing growth

Revenue
-62.8%
EBITDA
-57.5%
EBIT
-47.0%
EPS
-14.9%
Free cash flow
-72.4%
Operating cash flow
-76.6%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
+13.9%
EBITDA
-77.7%
EBIT
-59.8%
Net income
-58.6%
EPS
-35.7%
Free cash flow
—

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026